title: [Long-term treatment with intravitreal ranibizumab for exudative age-related macular degeneration].
abstract: BACKGROUND
  The results of intravitreal ranibizumab treatment for exsudative age-related macular degeneration have been favourable until this time.
  
  
  OBJECTIVE
  To evaluate the two-year functional and anatomic results of intravitreal ranibizumab treatment.
  
  
  METHODS
  46 patients (age: 75 ± 9.1 years) were included in a prospective single center study. Treatment regimen was the following: monthly 0.5 mg ranibizumab was administered in the first 3 months, and later as required (pro re nata). The change of best corrected visual acuity and central retinal thickness was followed.
  
  
  RESULTS
  The visus change at the end of the follow-up time was not statistically significant compared to baseline (p = 0.760) and the at the end of the first year (p = 0.154). Central retinal thickness decreased significantly compared to baseline (p = 0.000001), but the change was not statistically significant compared to the end of the first year (p = 0.875).
  
  
  CONCLUSIONS
  Patients with neovascular macular degeneration treated with intravitreal ranibizumab using pro re nata regimen have stable visus for long term, and the exsudation could be reduced efficiently.
authors.affiliation: Semmelweis Egyetem, Általános Orvostudományi Kar Szemészeti Klinika Budapest Mária u. 39. 1085 Fejér Megyei Szent György Egyetemi Oktató Kórház Székesfehérvár.
authors.forename: Regina
authors.initials: R
authors.lastname: Lukács
authors.forename: Miklós
authors.initials: M
authors.lastname: Resch
authors.forename: András
authors.initials: A
authors.lastname: Papp
authors.forename: Antal
authors.initials: A
authors.lastname: Szabó
authors.forename: Ágnes
authors.initials: Á
authors.lastname: Borbándy
authors.forename: Hanna
authors.initials: H
authors.lastname: Menkens
authors.forename: Huba
authors.initials: H
authors.lastname: Kiss
authors.forename: János
authors.initials: J
authors.lastname: Németh
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab; D012160:Retina / Q000187:drug effects* / Q000473:pathology; D019233:Retreatment; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000188:drug therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab
keywords: age-related macular degeneration; időskori maculadegeneráció; intravitreal injection; intravitrealis injekció; optical coherence tomography; optikai koherencia tomográfia; ranibizumab